Cell proliferation regulated by estradiol receptor: Therapeutic implications
Cell proliferation regulated by estradiol receptor: Therapeutic implications
复制标题
DOI：
10.1016/j.steroids.2009.10.007
复制
发表时间：
2010-08-01
期刊：
影响因子：
2.7
通讯作者：
Auricchio, Ferdinando
中科院分区：
文献类型：
--
作者：
Castoria, Gabriella;Migliaccio, Antimo;Auricchio, Ferdinando
雌激素受体（ER）是一种配体调控的转录因子，控制人乳腺癌细胞的增殖。大约60-70%的人乳腺癌表达ER。尽管人类乳腺癌的治疗取得了重大进展，但许多患者对药物治疗产生耐药性并发展为转移性乳腺肿瘤。已经提出了几种机制来解释肿瘤进展和对治疗的抗性。然而，乳腺癌依赖性进展的原因以及治疗耐药性仍有争议。越来越多的证据表明，在乳腺癌细胞中，除了其经典的转录作用，ER刺激增殖和抗凋亡信号通路，以响应配体结合或生长因子。这一发现导致了新化合物的合成，特别是干扰ER介导的快速反应。它还表明，目前用于乳腺癌治疗的方式需要重新考虑。(C)2009 Elsevier Inc. All rights reserved.
Estrogen receptor (ER) is a ligand-regulated transcription factor that controls human breast cancer cell proliferation. About 60-70% of human breast cancers express ER. In spite of major progress in the therapy of human breast cancer, many patients become resistant to pharmacologic treatments and develop metastatic breast tumors. Several mechanisms have been proposed to explain tumor progression and resistance to the therapies. However, the causes of hormone-dependent breast tumor progression as well as therapy resistance are still debated. An increasing body of evidence from our and other laboratories shows that in breast cancer cells, in addition to its classical transcriptional action, ER stimulates proliferative and anti-apoptotic signaling pathways in response to either ligand binding or growth factors. This discovery has led to the synthesis of new compounds specifically interfering in the rapid responses mediated by ER. It also suggests that the modalities currently in use for breast cancer treatment need to be reconsidered. (C) 2009 Elsevier Inc. All rights reserved.